Drug Trial Radar · NCT07237048
Minocycline in Stroke Study at Maimonides
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,164
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Dec 1, 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Joyce ChenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale
Conditions
- Stroke
- Ischemia Stroke
- Hemorrhagic Strokes
- Mortality
- Morbidity
- Cerebrovascular Accident (Stroke)
- Intracerebral Haemorrhage (ICH)
Interventions
Minocycline 200mgDrug
Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in National Institutes of Health Stroke Scale (NIHSS) Score at Day 7 post strokeTime frame: At day 7 after stroke onset
- Change in National Institutes of Health Stroke Scale (NIHSS) Score at 90 days (+/- 7 days) post-strokeTime frame: At 90 days (+/- 7 days) after stroke onset
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maimonides Medical Center
Brooklyn, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.